Union Strong Secures RMB 100 Million Series D+ Financing to Accelerate High-Quality Development in China's Medical and Health Industry

VCBeat learned at the earliest opportunity that, recently, Union Strong (Beijing) Tech. Co. Ltd (hereinafter referred to as “Union Strong^®”) secured over RMB 100 million in its Series D+ financing round, led by the Beijing Medical and Health Industry Investment Fund (hereinafter referred to as the “Beijing Medical Industry Fund”), with participation from the Beijing Economic-Technological Development Area Industrial Upgrade Equity Investment Fund (hereinafter referred to as the “Yizhuang Industrial Upgrade Fund”).

This financing round not only recognizes the company’s technological prowess and market potential, but also provides strong support for Beijing’s strategy to build a world-class biomedical industry cluster, marking Union Strong^®Took a solid step forward in promoting the innovative development of China's pharmaceutical and health industry.

Beijing Pharmaceutical Industry Fund led this round of financing, fully demonstrating its confidence in Union Strong^®This confidence in technological innovation and commercialization capabilities also reflects profound insights into and strategic planning for the future development of Beijing’s medical and healthcare industry. The co-investment by the Yizhuang Industrial Upgrade Fund further strengthens the company’s strategic position in regional industrial upgrading, providing solid support for its rapid growth both within the region and across China.

As a leading enterprise in the field of intelligent diagnosis and treatment of cerebrovascular diseases, Union Strong^®Always at the forefront of technology, we continuously explore and drive industrial upgrading. Following this round of financing, the company plans to further integrate its core product—the intelligent surgical solution for intracranial aneurysms—into its smart manufacturing system. By introducing advanced flexible production lines, we will achieve automation in the production process. This industrial upgrade will not only significantly enhance production efficiency and market responsiveness but also enable precise control over manufacturing processes and continuous quality optimization, thereby leading the industry chain in this field toward intelligent and automated transformation.

The introduction of intelligent manufacturing will also help address the issue of uneven distribution of medical resources. By optimizing production processes and resource allocation, Union Strong^®This approach more efficiently meets the demand for high-end medical equipment across different regions and hospitals, enabling more patients to access high-quality medical services in a timelier manner. In particular, patients in remote areas no longer need to travel long distances to major cities in search of treatment opportunities, thereby improving the accessibility and equity of healthcare services, alleviating the strain on medical resources, and promoting the balanced development of healthcare service capabilities.

Union Strong^®Since its establishment, the company has been committed to the development of products that are independently researched, originally created, and manufactured in China. By addressing core clinical pain points and leveraging deep collaborative R&D through medical-engineering integration, it delivers revolutionary solutions to the healthcare sector, filling international gaps in this technological field.

Intelligent Solutions for Intracranial Aneurysm Surgery represent one of the company’s significant achievements in the intelligent diagnosis and treatment of cerebrovascular diseases. This solution addresses a critical bottleneck in Level 4 (the highest difficulty) neurosurgical procedures: microcatheter shaping. It provides physicians with precise surgical planning and simulation, automatically generates microcatheter shaping protocols, and enables “fully autonomous” execution of key surgical steps, thereby effectively reducing surgical risks and improving success rates. In the future, with the deepening application of intelligent manufacturing, the production efficiency and performance of this solution will be further enhanced, bringing greater benefits to more patients.

Furthermore, this solution boasts robust scalability and customization capabilities. Building upon microcatheter shaping, the company is continuously developing simulation and selection functionalities for a wide variety of neurointerventional consumables. It provides personalized solutions and services tailored to the specific needs of different hospitals and physicians, thereby meeting diverse clinical requirements. This flexibility and customization capability have positioned Union Strong advantageously in the competitive market.

In addition to its intelligent surgical solutions for intracranial aneurysms, another core product from Union Strong—the Intracranial Aneurysm Auxiliary Assessment Software—has also attracted significant attention. This software is the first “AI + Decision-Making” product in China to enter the National Medical Products Administration’s (NMPA) Special Approval Procedure for Innovative Medical Devices. It provides precise assessments of intracranial aneurysm stability, offering clinicians critical support for treatment decision-making. By comprehensively analyzing factors such as aneurysm size, morphology, and location, along with patient examination indicators, personal characteristics, and family medical history, the software enables physicians to more accurately predict aneurysm stability. This facilitates the formulation of more scientific and rational treatment plans, thereby avoiding both overtreatment and undertreatment.

In 2022, this solution was included in the “Open Competition” list for AI Medical Device Innovation Tasks, jointly released by the Ministry of Industry and Information Technology (MIIT) and the National Medical Products Administration (NMPA). In 2024, it was honored as an Outstanding Unit in the Open Competition. Looking ahead, with further market expansion and penetration, this software will demonstrate strong market potential. Together with intelligent surgical solutions, it will reshape key decision-making and treatment processes in the clinical diagnosis and management of cerebrovascular diseases, delivering more precise and safer diagnostic and therapeutic services to a broader patient population.

As a member of Beijing's pharmaceutical and health industry, Union Strong^®It plays an active role in promoting technological innovation, industrial upgrading, and market expansion. Through close collaboration and resource sharing with upstream and downstream enterprises, Union Strong® continuously broadens the scope and depth of the industrial chain. In various stages including raw material supply, product research and development, manufacturing, and market promotion, Union Strong^®All parties are able to achieve complementary advantages and mutual benefits through collaboration with partners. This model of coordinated development not only enhances the overall competitiveness of the industrial chain but also promotes rapid and sustainable regional economic growth. Such an innovation-driven development model is a vivid manifestation of new quality productive forces in the pharmaceutical and healthcare sector. With the injection of capital, Union Strong® will accelerate technological innovation and product R&D, facilitate the implementation and application of more intelligent surgical solutions, and contribute greater momentum to the rapid development of Beijing’s biopharmaceutical industry.

Union Strong^®Qin Lan, Founder, Chairman, and General Manager“We are deeply honored to have earned the favor and support of the Beijing Pharmaceutical Industry Fund and the Yizhuang Industrial Upgrade Fund. The success of this financing round not only provides robust support for the company’s future development but also strengthens our resolve to respond to policy calls and drive industrial innovation. This funding will empower us to deepen our engagement in the field of AI-driven healthcare, promote technological innovation and industrial upgrading, and contribute more significantly to the development of Beijing’s biopharmaceutical industry and the enhancement of new quality productive forces. By introducing intelligent manufacturing technologies, we will further improve product production efficiency and quality, providing patients with safer, more efficient, and personalized diagnostic and therapeutic services. We look forward to working hand in hand with more partners to jointly promote the coordinated development of the pharmaceutical and health industries.”

Nie Hong, Managing Partner at Shanlan CapitalXinstated: “As a country with a high incidence of cerebrovascular disease, China has a massive patient base for both ischemic and hemorrhagic stroke. However, due to gaps in surgical adoption and emergency care processes compared to Europe and the United States, China’s surgical penetration rate remains low. Union Strong^®As China’s largest AI-powered platform for stroke diagnosis and treatment, Union Strong boasts an excellent and diverse team of top-tier experts, maintaining a leading position in the development and application of AI technologies for intelligent diagnosis and treatment of cerebrovascular diseases in China.^®Representative AI big data technologies and applications have been serving and empowering clinical practice in the field of precision diagnosis and treatment of cerebrovascular diseases, benefiting more cerebrovascular disease patients in China.”

Relevant Person in Charge of the Yizhuang Industrial Upgrading Fundstated: “The success of this funding round will inject strong momentum into the industrial upgrading of the Economic and Technological Development Zone. Through in-depth research and scientific evaluation, high-quality projects with core competitiveness and high growth potential have been selected. By leveraging capital market operations, we aim to improve the industrial chain structure of the Economic and Technological Development Zone, promote the upgrading and optimization of traditional industries, and enhance overall industrial standards. This round of investment in Union Strong^®financing support, is another important measure by the Industrial Upgrade Fund to precisely empower the high-quality development of the pharmaceutical and health industry, reflecting the Beijing Economic-Technological Development Area’s high regard for innovative enterprises. We look forward to Union Strong^®Continuously achieving breakthroughs in the fields of intelligent manufacturing and AI-driven diagnosis and treatment of cerebrovascular diseases, contributing to the innovative development of the pharmaceutical and health industries in the Beijing Economic-Technological Development Area and across China.”

With the successful completion of the Series D+ financing round, Union Strong^®It will usher in a new phase of development, continuously increasing investments in technological innovation, talent acquisition, and market expansion. By breaking through technical barriers and broadening application scenarios, the company aims to facilitate the implementation and promotion of more innovative products. Meanwhile, it will actively collaborate with upstream and downstream enterprises across the industrial chain to jointly promote the coordinated development of the pharmaceutical and healthcare industry, thereby contributing to the rapid growth of the regional economy.

Looking Ahead, Union Strong^®We will always uphold the corporate mission of “AI-empowered healthcare, technology safeguarding lives,” driving development through innovation and leading the future with technology. The company will continue to deepen its expertise in the intelligent diagnosis and treatment of cerebrovascular diseases, constantly launching more innovative products and technological solutions with independent intellectual property rights, thereby making greater contributions to enhancing China’s medical service standards and improving the health and well-being of its people.